Bratton Capital Management, L.P. has filed its latest 13F-HR report, revealing a total investment value of approximately $45.4 million as of September 30, 2026. This filing is significant as it provides insight into the firm’s investment strategies and positions within the market.

Bratton Capital Management, L.P., based in Fort Worth, Texas, is an investment management firm. The firm primarily engages in managing investments for clients, focusing on various sectors. Its recent filings include several 13F-HR reports, with the latest submission dated November 3, 2026, under accession number 0001315863-26-000765.

The filing indicates that Bratton Capital holds a substantial position in Aquestive Therapeutics Inc, with a total of 9,810,958 shares valued at $45,424,736. The investment is classified under "SOLE" investment discretion, meaning Bratton Capital has full control over the shares. The firm reported that it holds 100% voting authority over these shares.

This update may impact various stakeholders, including investors and analysts monitoring the investment management sector. The information disclosed is essential for understanding how Bratton Capital is positioning itself in the market, particularly with its significant stake in Aquestive Therapeutics.

The filing does not specify what actions Bratton Capital Management may take next regarding its holdings or any future investments.

Company Overview

Bratton Capital Management, L.P. is incorporated in Texas and operates out of Fort Worth, where it manages investments for a diverse clientele. The firm has a fiscal year that ends on December 31st, indicating its annual reporting cycle aligns with the calendar year.

Filing Details

The 13F-HR filing, submitted on November 3, 2026, is a quarterly report that provides the SEC with information about the firm’s holdings as of September 30, 2026. This report is crucial for transparency in the investment management industry, allowing stakeholders to assess the investment strategies employed by Bratton Capital.

Investment Strategy

While the filing highlights a significant investment in Aquestive Therapeutics Inc, it does not disclose any additional positions or sectors in which Bratton Capital may be investing. The absence of such information leaves a gap in understanding the full scope of the firm's investment strategy and diversification efforts.

“The investment management landscape is constantly evolving, and filings like these are key to understanding how firms like Bratton Capital are navigating the market.”